Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nyxoah ( (NYXH) ) has shared an announcement.
On July 28, 2025, Nyxoah announced the publication of data from its DREAM pivotal study in the Journal of Clinical Sleep Medicine, showcasing the Genio® system’s efficacy and safety over 12 months. The study revealed high patient satisfaction and consistent device usage, with significant reductions in apnea hypopnea burden and improvements in quality of life. These findings support Nyxoah’s PMA submission to the FDA and highlight the Genio® system’s potential impact on OSA treatment, positioning Nyxoah as a leader in innovative OSA solutions.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR18.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Their lead product, the Genio® system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy designed to address OSA, a common sleep disorder associated with increased mortality risk and cardiovascular comorbidities.
Average Trading Volume: 44,698
Current Market Cap: €235.8M
Find detailed analytics on NYXH stock on TipRanks’ Stock Analysis page.